nach oben

Drugs

Erschienen in:

01.02.2021 | AdisInsight Report

Setmelanotide: First Approval

verfasst von: Anthony Markham

Erschienen in: Drugs | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Setmelanotide (IMCIVREE™, Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity arising from proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The drug has received its first approval in the USA for chronic weight management in patients 6 years and older with obesity caused by POMC, PCSK1 and LEPR deficiency and has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4 receptor pathway. Setmelanotide is also being developed in other rare genetic disorders associated with obesity including Bardet–Biedl Syndrome, Alström Syndrome, POMC and other MC4R pathway heterozygous deficiency obesities, and POMC epigenetic disorders. This article summarizes the milestones in the development of setmelanotide leading to this first approval for obesity caused by POMC, PCSK1 and LEPR deficiency.

Rhythm Pharmaceuticals. Rhythm Pharmaceuticals announces FDA approval of IMCIVREE^TM (setmelanotide) as first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency [media release]. 27 Nov 2020. http://www.rhythmtx.com/.

Ryan DH. Setmelanotide: what does it mean for clinical care of patients with obesity? Lancet Diabetes Endocrinol. 2020;8(12):933–5.CrossRef

Kuhnen P, Clement K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–6.CrossRef

Rhythm Pharmaceuticals. Setmelanotide (IMCIVREE™): US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf. Accessed 2 Dec 2020.

US Food and Drug Administration. FDA approves first treatment for weight management for people with certain rare genetic conditions [media release]. 27 Nov 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions.

Ipsen Limited. Ipsen grants Rhythm exclusive worldwide license for two programs in the field of metabolic disorders [media release]. 12 Mar 2010. http://www.ipsen.com.

Rhythm Pharmaceuticals. Rhythm and Camurus announce license agreement for extended release FluidCrystal setmelanotide [media release]. 5 Jan 2016. http://www.rhythmtx.com.

Roubert P, Dubern B, Plas P, et al. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J Endocrinol. 2010;207(2):177–83.CrossRef

Thompson Z, Shah BP, Low MJ. Chronic treatment of juvenile hypothalamic POMC-deficient mice with RM-493 prevents the development of obesity [abstract no. SAT-299]. J Endocr Soc. 2020;4(Suppl):A166–7.

10.

Bischof JM, Van Der Ploeg LHT, Colmers WF, et al. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist. Br J Pharmacol. 2016;2016:2614–21.CrossRef

11.

Stephenson E, McAllan L, Stayton A, et al. Setmelanotide (RM-493) reduces food intake and rapidly induces weight loss in a mouse model of Alström syndrome [abstract no. MON-LB019]. J Endocr Soc. 2019;3(Suppl 1).

12.

Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62(2):490–7.CrossRef

13.

Chen KY, Muniyappa R, Abel BS, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015;100(4):1639–45.CrossRef

14.

Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.CrossRef

15.

Clement K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551–5.CrossRef

16.

Rhythm Pharmaceuticals. Rhythm Pharmaceuticals announces positive topline results from pivotal phase 3 clinical trial evaluating setmelanotide in Bardet-Biedl and Alström syndromes [media release]. 22 Dec 2020. https://ir.rhythmtx.com/.

17.

Haws R, Brady S, Davis E, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133–40.CrossRef

Titel: Setmelanotide: First Approval
verfasst von: Anthony Markham
Publikationsdatum: 01.02.2021
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 3/2021
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-021-01470-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Setmelanotide: First Approval

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease

Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review

Berotralstat: First Approval

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

Amisulpride: A Review in Post-Operative Nausea and Vomiting